What You Should Know:
– PathAI, a leader in AI-powered digital pathology solutions, announced today the launch of AIM-MASH on its AISight Image Management System (IMS).
– The new product offers advanced AI-based measurement tools to support pathologists in assessing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using the MASH Clinical Research Network (CRN) Activity Score.
AIM-MASH Integration with AISight
By integrating AIM-MASH with AISight, PathAI aims to improve the reproducibility, efficiency, and accuracy of MASH assessments. The AI-powered tools provide pathologists with valuable insights, including:
- Highly sensitive and specific review: AI overlays highlight key areas for evaluation, reducing the risk of missed findings.
- Repeatable and reproducible assessments: AI algorithms improve consistency in scoring compared to manual methods.
- Increased scoring confidence: AI-generated data supports pathologists’ assessments and enhances accuracy.
- Global collaboration: AISight IMS enables remote review of cases by expert pathologists.
“We are thrilled to introduce AIM-MASH on the AISight IMS platform,” said Andy Beck, MD, PhD, CEO of PathAI. “This product is a game-changer for drug development, as it supports pathologists in making high-quality, reproducible MASH assessments. With AIM-MASH on AISight, pathologists can increase their confidence in pathology reads and decision-making, as if they have the world’s expert liver pathologists assisting with every slide, helping with simplifying the complex task of scoring and evaluation.”
